FBIOP Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
$18,23
Prezzo · Ago 18, 2026
Fondamentali al Ago 13, 2026
Intervallo 52 sett.
$6–$21
79% of range
Rating Analisti
BUY
8 analysts
Prezzo Obiettivo
—
P/E (TTM)
-260.4
ROE
18.8%
Margine di Profitto Netto
10.8%
Informazioni su Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Panoramica della società da Wikipedia
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
Leggi di più
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
History
The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.
In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.
Subsidiaries
Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).
Products
Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.
== References ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
FBIOP Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$18.23
Capitalizzazione di Mercato
$572M
P/E (TTM)
-260.4
EPS (TTM)
$-0.07
Ricavi (TTM)
$63M
Rendimento div.
0.11%
ROE
18.8%
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$6 – $21
FBIOP Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$63M
2021-12-31
→
2025-12-31
EPS
$-0.07
2021-12-31
→
2025-12-31
Flusso di cassa libero
—
2021-12-31
→
2024-12-31
Margini
10.8%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
FBIOP
Mediana dei peer
P/E (TTM)
-260.4
28.5
P/S (TTM)
9.0
108.5
P/B
11.5
2.6
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
FBIOP
Mediana dei peer
Operating Margin (Margine Operativo)
-111.0%
—
Net Profit Margin (Margine di Profitto Netto)
10.8%
-2381.8%
ROA
4.1%
-60.0%
ROE
18.8%
-135.7%
ROIC
-138.2%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
FBIOP
Mediana dei peer
Current Ratio (Rapporto corrente)
2.5
2.2
Quick Ratio
2.2
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
FBIOP
Mediana dei peer
Revenue YoY (Ricavi YoY)
9.7%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
-5.8%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
6.8%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
FBIOP
Mediana dei peer
Payout Ratio (Rapporto di Distribuzione Utili)
9.7%
—
Dividendi Rendimento, payout ratio, storico dividendi, CAGR 5Y
Dividend Yield
0.11%
Rapporto di Distribuzione Utili
9.7%
CAGR Dividendi 5Y
—
| Data ex-dividendo | Importo |
|---|---|
| 14 Giugno 2024 | $0,1950 |
| 14 Maggio 2024 | $0,1950 |
| 12 Aprile 2024 | $0,1950 |
| 14 Marzo 2024 | $0,1950 |
| 14 Febbraio 2024 | $0,1950 |
| 11 Gennaio 2024 | $0,1950 |
| 14 Dicembre 2023 | $0,1950 |
| 14 Novembre 2023 | $0,1950 |
| 12 Ottobre 2023 | $0,1950 |
| 14 Settembre 2023 | $0,1950 |
| 14 Agosto 2023 | $0,1950 |
| 13 Luglio 2023 | $0,1950 |
| 14 Giugno 2023 | $0,1950 |
| 12 Maggio 2023 | $0,1950 |
| 13 Aprile 2023 | $0,1950 |
| 14 Marzo 2023 | $0,1950 |
| 14 Febbraio 2023 | $0,1950 |
| 12 Gennaio 2023 | $0,1950 |
| 14 Dicembre 2022 | $0,1950 |
| 14 Novembre 2022 | $0,1950 |
FBIOP Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
8 analisti
- Acquisto forte 2 25,0%
- Compra 5 62,5%
- Mantieni 1 12,5%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.10%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 31 Marzo 2026 | $-1.13 | $-0.22 | -0.91% |
| 31 Dicembre 2025 | $-0.01 | $0.11 | -0.12% |
| 30 Settembre 2025 | $0.11 | $-0.43 | 0.54% |
| 30 Giugno 2025 | $-0.50 | $-0.37 | -0.13% |
| 31 Marzo 2025 | $-0.48 | $-0.50 | 0.02% |
| 31 Dicembre 2024 | $-0.75 | $-0.77 | 0.02% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| FBIOP | $298M | -135.6 | 9.7% | 10.8% | 18.8% | — |
| INO | $120M | -1.0 | -70.0% | -130000.0% | -322.8% | — |
| ANIX | $136M | -12.1 | 0.00% | — | -62.2% | — |
| CADL | $310M | -7.8 | — | — | -53.7% | — |
| FBIO | — | — | — | — | — | — |
| BMEA | $90M | -1.1 | -67.1% | -3326.0% | -216.6% | — |
| GANX | $135M | -5.3 | -60.6% | — | -181.1% | — |
| ALDX | $312M | -9.2 | — | — | -68.0% | — |
| ICCC | — | -51.2 | 4.3% | — | — | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Cost of Revenue | $21M | $21M | $23M | $31M | $32M | $15M | $11M | $6M | $4M | $790.0K | $0 | · | |
| R&D Expense | · | · | $106M | $135M | $129M | $64M | $81M | $87M | $48M | $35M | $30M | $10M | |
| SG&A Expense | $96M | $88M | $91M | $114M | $87M | $61M | $56M | $53M | $51M | $28M | $19M | $10M | |
| Operating Expenses | $133M | $168M | $227M | $279M | $257M | $140M | $147M | $147M | $107M | $82M | $51M | $21M | |
| Operating Income | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-90M | $-66M | $-51M | $-21M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $4M | $1M | $1M | |
| Interest Income | $2M | $3M | $3M | $1M | $649.0K | $2M | $3M | $1M | $819.0K | $298.0K | $245.0K | $662.0K | |
| Other Non-op | $18M | $1M | $-3M | $1M | $24M | $-9M | $9M | $-11M | $-8M | $-6M | $-3M | $266.0K | |
| Pretax Income | $-34M | $-121M | $-154M | $-213M | $-164M | $-103M | $-102M | $-131M | $-98M | $-71M | $-54M | · | |
| Income Tax | $-620.0K | $312.0K | $521.0K | $449.0K | $500.0K | $500.0K | $0 | $0 | $2M | $0 | $0 | · | |
| Net Income | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| EPS (Basic) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| Shares (Basic) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| EBITDA | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-100M | $-65M | $-51M | · |
Stato Patrimoniale 29
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79M | $57M | $81M | $178M | $306M | $233M | $137M | $66M | $95M | $105M | $98M | $50M | |
| Short-term Investments | · | · | · | · | · | · | $0 | $18M | $36M | $0 | · | $20M | |
| Receivables | $30M | $10M | $15M | $28M | $23M | $24M | $14M | $5M | $8M | $2M | $0 | · | |
| Inventory | $10M | $14M | $10M | $14M | $10M | $1M | $857.0K | $678.0K | $171.0K | $203.0K | $0 | · | |
| Prepaid Expense | $5M | $7M | $10M | $10M | $7M | $7M | $4M | $7M | $6M | $9M | $2M | $702.0K | |
| Current Assets | $124M | $90M | $117M | $230M | $346M | $266M | $156M | $111M | $183M | $110M | $100M | $70M | |
| PP&E (Net) | $3M | $3M | $7M | $13M | $15M | $12M | $12M | $12M | $7M | $7M | $309.0K | $52.0K | |
| PP&E (Gross) | $8M | $15M | $15M | $25M | $24M | $19M | $17M | $15M | $8M | · | $377.0K | $94.0K | |
| Accum. Depreciation | $3M | $10M | $9M | $12M | $9M | $7M | $4M | $3M | $1M | · | $68.0K | $42.0K | |
| Goodwill | · | · | · | · | · | · | · | · | $19M | $19M | $0 | · | |
| Intangibles | $28M | $32M | $20M | $27M | $13M | $15M | $7M | $1M | $883.0K | $17M | $1M | $0 | |
| Other Non-current Assets | $401.0K | $731.0K | $4M | $973.0K | $1M | $1M | $1M | $276.0K | $258.0K | $394.0K | $43.0K | $64.0K | |
| Total Assets | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Accounts Payable | $14M | $32M | $35M | $57M | $47M | $11M | $35M | $34M | $27M | $2M | $10M | $366.0K | |
| Accrued Liabilities | $47M | $66M | $74M | $97M | $91M | $45M | $25M | $16M | $18M | $10M | $9M | $4M | |
| Short-term Debt | · | · | · | · | · | $0 | $7M | · | · | · | · | $0 | |
| Current Liabilities | $50M | $71M | $85M | $128M | $101M | $52M | $46M | $56M | $71M | $57M | $11M | $4M | |
| Capital Leases | $13M | $15M | $18M | $22M | $21M | $23M | $24M | $0 | · | · | · | · | |
| Deferred Tax | · | · | $233.0K | $0 | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $5M | $5M | $5M | $584.0K | $722.0K | |
| Total Liabilities | $123M | $146M | $166M | $244M | $171M | $136M | $154M | $121M | $125M | $88M | $34M | $19M | |
| Long-term Debt | $54M | $58M | $61M | $92M | $43M | $52M | $85M | $84M | $68M | $30M | $24M | $14M | |
| Total Debt | · | · | · | · | · | $0 | · | · | · | · | · | · | |
| Common Stock | $31.0K | $28.0K | $15.0K | $7.0K | $101.0K | $95.0K | $74.0K | $58.0K | $51.0K | $49.0K | $47.0K | $46.0K | |
| Paid-in Capital | $784M | $764M | $717M | $676M | $656M | $583M | $462M | $397M | $364M | $284M | $247M | $212M | |
| Retained Earnings | $-734M | $-741M | $-695M | $-634M | $-547M | $-483M | $-436M | $-396M | $-312M | $-245M | $-190M | $-142M | |
| Stockholders' Equity | $50M | $23M | $23M | $42M | $109M | $100M | $26M | $2M | $53M | $38M | $57M | $71M | |
| Liabilities + Equity | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Shares Outstanding | 31,364,094 | 27,908,839 | 15,093,053 | 7,366,283 | 101,435,505 | 94,877,492 | 74,027,425 | 57,845,447 | 50,991,285 | 48,932,023 | 47,147,032 | 46,494,034 |
Flusso di cassa 18
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | $1M | $944.0K | $26.0K | $23.0K | |
| Stock-based Comp | $29M | $33M | $17M | $23M | $19M | $13M | $13M | $15M | $13M | $12M | $14M | $6M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $0 | $-73.0K | $0 | $0 | |
| Amort. of Intangibles | $4M | $3M | $4M | $4M | · | $1M | $1M | · | $2M | $0 | $0 | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | $-34M | $-4M | $14M | · | |
| Operating Cash Flow | $-66M | $-80M | $-128M | $-179M | $-117M | $-84M | $-95M | $-99M | $-81M | $-46M | $-20M | $-16M | |
| CapEx | · | $0 | $63.0K | $3M | $5M | $2M | $2M | $7M | $648.0K | $6M | $283.0K | $0 | |
| Investing Cash Flow | $10M | $-15M | $-2M | $-23M | $41M | $-7M | $20M | $19M | $-40M | $-6M | $8M | · | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Issued | $1M | $4M | $2M | $6M | $9M | $46M | $21M | $10M | · | $0 | $0 | $4M | |
| Stock Repurchased | · | · | · | · | · | $70.0K | $0 | · | · | · | · | · | |
| Net Stock Activity | $1M | $4M | $2M | $6M | $9M | $47M | · | $10M | · | $0 | $0 | · | |
| Dividends Paid | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $77M | $71M | $33M | $75M | $149M | $172M | $147M | $51M | $150M | $43M | $61M | · | |
| Net Change in Cash | $22M | $-25M | $-98M | $-127M | $73M | $82M | $72M | $-29M | $29M | $-9M | $48M | $-50M | |
| Taxes Paid | $49.0K | $120.0K | $-55.0K | $858.0K | $993.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-80M | $-128M | $-182M | $-121M | $-86M | $-97M | $-106M | $-88M | $-52M | $-21M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | $-93M | · | · | · |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.9% | -398.7% | -5855.3% | · | |
| Net Margin | 10.8% | -79.8% | -71.8% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.6% | -334.3% | -5611.6% | · | |
| Pretax Margin | -53.0% | -209.0% | -181.8% | -281.8% | -238.9% | -225.6% | -277.5% | -486.6% | -52.4% | · | · | · | |
| EBITDA Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.3% | -393.0% | -5852.3% | · | |
| ROA | 4.1% | -33.9% | -26.3% | -25.1% | -17.7% | -16.7% | -21.8% | -43.5% | -32.1% | -34.8% | -47.1% | · | |
| ROE | 18.8% | -203.2% | -188.7% | -115.1% | -61.9% | -73.5% | -284.8% | -309.2% | -146.9% | -115.6% | -76.0% | · | |
| ROIC | -138.2% | -486.7% | -633.5% | -488.9% | -174.0% | -94.1% | -422.7% | -6479.3% | -195.5% | · | · | · |
Liquidità e Solvibilità 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.3 | 1.4 | 1.8 | 3.4 | 5.5 | 3.4 | 2.0 | 2.7 | 1.9 | 9.4 | · | |
| Quick Ratio | 2.2 | 0.9 | 1.1 | 1.6 | 3.3 | 5.3 | 3.3 | 1.6 | 2.3 | 1.6 | 9.3 | · | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -17.3 | -17.8 | -34.1 | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.9 | 0.1 | 0.0 | · | |
| Inventory Turnover | 1.7 | 1.7 | 2.2 | 2.6 | 5.7 | 12.9 | 13.7 | 14.4 | 19.6 | -7.8 | · | · | |
| Receivables Turnover | 3.2 | 4.5 | 3.9 | 3.0 | 2.9 | 2.8 | 3.8 | 4.1 | 39.1 | 18.0 | · | · |
Tassi di Crescita 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 9.7% | -31.8% | 11.6% | 10.1% | 50.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -5.8% | -5.7% | 22.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Net Income TTM | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| Market Cap | $298M | $186M | $179M | $1.95B | $2.63B | $1.84B | $1.52B | $832M | $1.16B | · | · | · | |
| Enterprise Value | · | · | · | · | · | $1.61B | · | · | · | · | · | · | |
| P/E | -135.6 | -2.5 | -1.4 | -1.1 | -32.8 | · | · | · | · | · | · | · | |
| P/S | 4.7 | 3.2 | 2.1 | 25.7 | 38.2 | 40.3 | 41.4 | 31.0 | 67.3 | · | · | · | |
| P/B | 6.0 | 8.2 | 7.9 | 46.7 | 24.2 | 18.3 | 57.8 | 449.4 | 22.1 | · | · | · | |
| P / Tangible Book | 13.4 | · | 79.4 | 134.3 | 27.3 | 21.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.5 | -2.3 | -1.4 | -10.9 | -22.5 | -22.0 | -16.0 | -8.4 | -13.6 | · | · | · | |
| P / FCF | · | -2.3 | -1.4 | -10.7 | -21.7 | -21.5 | -15.6 | -7.9 | -13.3 | · | · | · | |
| EV / EBITDA | · | · | · | · | · | -17.0 | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | -18.8 | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | 35.2 | · | · | · | · | · | · | |
| Dividend Yield | 0.22% | 0.37% | 0.41% | 0.04% | 0.03% | 0.01% | 0.00% | · | · | · | · | · | |
| Earnings Yield | -0.74% | -40.5% | -71.4% | -90.5% | -3.0% | · | · | · | · | · | · | · | |
| Payout Ratio | 9.7% | -1.5% | -1.2% | -0.87% | -1.2% | -0.51% | · | · | · | · | · | · | |
| Annual Payout | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $16M | $16M | $18M | $16M | $13M | $15M | $15M | $15M | $13M | $20M | $35M | $17M | $12M | $16M | $17M | |
| Cost of Revenue | $6M | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $6M | $6M | $2M | $6M | $8M | $6M | $8M | $7M | |
| R&D Expense | · | · | · | · | · | · | · | $9M | $13M | $25M | · | $20M | $32M | $40M | $35M | $30M | |
| SG&A Expense | $21M | $16M | $15M | $17M | $39M | $26M | $27M | $22M | $21M | $18M | $19M | $22M | $24M | $25M | $28M | $30M | |
| Operating Expenses | $29M | $24M | $21M | $24M | $53M | $35M | $39M | $37M | $43M | $50M | $40M | $49M | $67M | $71M | $71M | $67M | |
| Operating Income | $-10M | $-8M | $-5M | $-7M | $-36M | $-22M | $-24M | $-22M | $-28M | $-37M | $-20M | $-14M | $-50M | $-59M | $-55M | $-51M | |
| Interest Income | $2M | $570.0K | $637.0K | $736.0K | $622.0K | $490.0K | $527.0K | $589.0K | $734.0K | $833.0K | $705.0K | $547.0K | $715.0K | $1M | $687.0K | $419.0K | |
| Other Non-op | $11M | $1M | $-20.0K | $18M | $-62.0K | $-12.0K | $-14.0K | $1M | $282.0K | $-21.0K | $-5M | $620.0K | $395.0K | $304.0K | $6M | $648.0K | |
| Pretax Income | $922.0K | $142M | $-6M | $9M | $-12M | $-25M | $-26M | $-27M | · | · | $-29M | $-11M | · | · | $-57M | $-53M | |
| Income Tax | $320.0K | $5M | $-646.0K | $26.0K | $0 | $0 | $243.0K | $69.0K | $0 | $0 | $380.0K | $141.0K | $0 | $0 | $449.0K | $0 | |
| Net Income | $-468.0K | $110M | $-4M | $6M | $15M | $-11M | $-7M | $-13M | $-11M | $-15M | $-9M | $-5M | $-25M | $-22M | $-27M | $-23M | |
| EPS (Basic) | $-0.08 | $3.44 | $-0.22 | $0.13 | $0.50 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-0.41 | $-0.94 | $-3.65 | $-3.47 | $-11.39 | $-4.11 | |
| EPS (Diluted) | $-0.08 | $2.82 | $-0.15 | $0.11 | $0.45 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-3.67 | $-0.94 | $-3.65 | $-0.21 | $-11.42 | $-4.11 | |
| Shares (Basic) | 31,791,173 | 31,540,595 | -52,672,183 | 27,244,474 | 26,879,380 | 26,450,218 | -34,381,775 | 19,697,290 | 18,316,874 | 17,151,945 | -13,557,455 | 7,498,653 | 7,377,332 | 6,792,376 | -175,035,295 | 5,961,663 | |
| Shares (Diluted) | 31,791,173 | 38,412,716 | -61,473,472 | 33,100,961 | 29,824,182 | 26,450,218 | -34,381,775 | 19,697,290 | 18,316,874 | 17,151,945 | -108,650,727 | 7,498,653 | 7,377,332 | 101,885,648 | -175,035,295 | 5,961,663 | |
| EBITDA | $-10M | $-8M | · | $-7M | $-36M | $-22M | · | $-22M | $-28M | $-37M | · | $-14M | $-50M | $-59M | · | $-51M |
Stato Patrimoniale 27
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197M | $256M | $79M | $86M | $74M | $91M | $57M | $59M | $76M | $84M | $81M | $72M | $78M | $152M | $178M | $208M | |
| Receivables | $36M | $25M | $30M | $18M | $16M | $18M | $10M | $11M | $10M | $10M | $15M | $8M | $17M | $28M | $28M | $29M | |
| Inventory | $8M | $9M | $10M | $12M | $13M | $12M | $14M | $12M | $10M | $11M | $10M | $11M | $12M | $13M | $14M | $15M | |
| Prepaid Expense | $4M | $5M | $5M | $2M | $7M | $5M | $7M | $3M | $5M | $12M | $10M | $6M | $7M | $8M | $10M | $6M | |
| Current Assets | $246M | $295M | $124M | $119M | $110M | $127M | $90M | $86M | $103M | $117M | $117M | $98M | $128M | $202M | $230M | $258M | |
| PP&E (Net) | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $6M | $7M | $7M | $7M | $12M | $13M | $14M | |
| PP&E (Gross) | $7M | $7M | $8M | $8M | $8M | $8M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $25M | $25M | $25M | |
| Accum. Depreciation | $3M | $2M | $3M | $3M | $3M | $3M | $10M | $12M | $10M | $9M | $9M | $9M | $8M | $13M | $12M | $12M | |
| Intangibles | $26M | $26M | $28M | $29M | $30M | $31M | $32M | $18M | $19M | $19M | $20M | $21M | $22M | $26M | $27M | $28M | |
| Other Non-current Assets | $1M | $740.0K | $401.0K | $18M | $3M | $3M | $731.0K | $3M | $3M | $4M | $4M | $5M | $4M | $943.0K | $973.0K | $1M | |
| Total Assets | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Accounts Payable | $12M | $14M | $14M | $19M | $20M | $28M | $32M | $34M | $38M | $42M | $35M | $45M | $49M | $66M | $57M | $56M | |
| Accrued Liabilities | $49M | $93M | $47M | $45M | $49M | $66M | $66M | $64M | $69M | $76M | $74M | $81M | $99M | $105M | $97M | $94M | |
| Short-term Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $62M | $103M | $50M | $54M | $58M | $74M | $71M | $70M | $76M | $88M | $85M | $97M | $129M | $129M | $128M | $106M | |
| Capital Leases | $11M | $12M | $13M | $13M | $13M | $14M | $15M | $15M | $16M | $18M | $18M | $19M | $20M | $21M | $22M | $21M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Other Non-current Liabilities | $3M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $111M | $154M | $123M | $116M | $123M | $146M | $146M | $140M | $160M | $169M | $166M | $164M | $197M | $244M | $244M | $222M | |
| Long-term Debt | $35M | $38M | $52M | $48M | $50M | $56M | $58M | $52M | $67M | $61M | $61M | $46M | $55M | $92M | $92M | $91M | |
| Total Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $33.0K | $33.0K | $31.0K | $31.0K | $30.0K | $30.0K | $28.0K | $28.0K | $23.0K | $19.0K | $15.0K | $9.0K | $132.0K | $130.0K | $7.0K | $108.0K | |
| Paid-in Capital | $788M | $786M | $784M | $786M | $780M | $774M | $764M | $755M | $739M | $733M | $717M | $702M | $699M | $693M | $676M | $669M | |
| Retained Earnings | $-624M | $-624M | $-734M | $-730M | $-736M | $-751M | $-741M | $-734M | $-721M | $-710M | $-695M | $-686M | $-681M | $-656M | $-634M | $-607M | |
| Stockholders' Equity | $164M | $162M | $50M | $56M | $44M | $22M | $23M | $21M | $18M | $23M | $23M | $17M | $19M | $38M | $42M | $62M | |
| Liabilities + Equity | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Shares Outstanding | 33,311,012 | 33,186,671 | 31,364,094 | 31,005,170 | 29,752,795 | 29,554,966 | 27,908,839 | 27,584,600 | 22,587,038 | 19,375,343 | 15,093,053 | 8,937,587 | 131,657,369 | 130,417,161 | 7,366,283 | 108,259,353 |
Flusso di cassa 12
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | $2M | $3M | $17M | $6M | $16M | $7M | $5M | $5M | $4M | $4M | $4M | $5M | $6M | $7M | |
| Amort. of Intangibles | $969.0K | $1M | $1M | $1M | $1M | $1M | $982.0K | $814.0K | $814.0K | $814.0K | $815.0K | $814.0K | $1M | $1M | $1M | $1M | |
| Operating Cash Flow | $-59M | $204M | $-13M | $-6M | $-28M | $-20M | $-13M | $-20M | $-22M | $-25M | $-35M | $-17M | $-33M | $-43M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | $0 | · | · | $28.0K | $1.0K | $34.0K | $0 | $91.0K | $980.0K | |
| Investing Cash Flow | $-79.0K | $0 | $0 | $3M | $6M | $1M | $-15M | $0 | $0 | $0 | $-63.0K | $5M | $-2M | $-5M | $-391.0K | $-893.0K | |
| Stock Issued | · | $0 | $0 | $0 | $-1.0K | $1M | $340.0K | $568.0K | $2M | $894.0K | $-15.0K | $888.0K | $721.0K | $447.0K | $303.0K | $223.0K | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | $894.0K | · | · | · | $447.0K | · | · | |
| Dividends Paid | · | $0 | $166.0K | $166.0K | $166.0K | $166.0K | $166.0K | $176.0K | $176.0K | $176.0K | $180.0K | $185.0K | $185.0K | $186.0K | $186.0K | $188.0K | |
| Financing Cash Flow | $91.0K | $-27M | $6M | $15M | $5M | $52M | $26M | $3M | $14M | $28M | $44M | $-3M | $-30M | $22M | $19M | $4M | |
| Net Change in Cash | $-59M | $176M | $-7M | $12M | $-17M | $34M | $-2M | $-17M | $-8M | $2M | $9M | $-14M | $-66M | $-26M | $-30M | $-40M | |
| Taxes Paid | · | · | $0 | $0 | · | · | $5.0K | $0 | $115.0K | $0 | $-38.0K | $35.0K | $52.0K | $-104.0K | $-604.0K | $1M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-43M | · | · |
Redditività 7
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| Net Margin | -2.5% | 688.2% | · | 33.2% | 94.3% | -80.5% | · | -88.0% | -73.5% | -118.3% | · | -14.5% | -142.5% | -173.3% | · | -136.2% | |
| Pretax Margin | 4.9% | 887.2% | · | 50.2% | · | · | · | -182.0% | · | · | · | -30.4% | · | · | · | · | |
| EBITDA Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| ROA | -0.20% | 41.3% | · | 3.8% | 10.1% | -6.2% | · | -9.3% | -6.7% | -7.2% | · | -2.1% | -9.1% | -6.4% | · | -6.2% | |
| ROE | -0.45% | 119.7% | · | 15.2% | 50.1% | -46.8% | · | -68.0% | -60.2% | -50.7% | · | -12.9% | -51.8% | -31.8% | · | -29.2% | |
| ROIC | -3.9% | -4.5% | · | -12.2% | · | · | · | -104.7% | · | · | · | -83.6% | · | · | · | · |
Liquidità e Solvibilità 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.9 | · | 2.2 | 1.9 | 1.7 | · | 1.2 | 1.4 | 1.3 | · | 1.0 | 1.0 | 1.6 | · | 2.4 | |
| Quick Ratio | 3.8 | 2.7 | · | 1.9 | 1.6 | 1.5 | · | 1.0 | 1.1 | 1.1 | · | 0.8 | 0.7 | 1.4 | · | 2.2 | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.5 | 0.4 | 0.4 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.4 | · | 0.5 | |
| Receivables Turnover | 0.7 | 0.7 | · | 1.2 | 1.3 | 0.9 | · | 1.6 | 1.1 | 0.7 | · | 1.9 | 0.8 | 0.4 | · | 0.5 |
Valutazione (TTM) 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $63M | · | $62M | $59M | $56M | · | $77M | $80M | $78M | · | $81M | $65M | $72M | · | $80M | |
| Net Income TTM | $131M | $121M | · | $-2M | $-19M | $-50M | · | $-44M | $-56M | $-67M | · | $-74M | $-90M | $-81M | · | $-80M | |
| Market Cap | $670M | $462M | · | $285M | $229M | $178M | · | $150M | $359M | $322M | · | $105M | $2.30B | $2.40B | · | $2.03B | |
| Enterprise Value | $478M | $208M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 6.1 | 4.8 | · | -13.5 | -5.1 | -2.0 | · | -1.6 | -2.5 | -2.8 | · | -1.3 | -2.1 | -3.9 | · | -3.9 | |
| P/S | 9.7 | 7.3 | · | 4.6 | 3.9 | 3.2 | · | 1.9 | 4.5 | 4.1 | · | 1.3 | 35.3 | 33.4 | · | 25.3 | |
| P/B | 4.1 | 2.8 | · | 5.1 | 5.2 | 8.0 | · | 7.1 | 20.1 | 14.0 | · | 6.3 | 124.5 | 63.5 | · | 32.9 | |
| P / Tangible Book | 4.8 | 3.4 | · | 10.5 | 16.1 | · | · | 45.4 | · | 90.5 | · | · | · | 205.7 | · | 61.1 | |
| P / Cash Flow | · | 2.3 | · | · | · | -9.1 | · | · | · | -12.7 | · | · | · | -55.5 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | -55.5 | · | · | |
| EV / EBITDA | -47.8 | -26.9 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.9 | 3.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 16.4% | 20.8% | · | -7.4% | -19.7% | -50.1% | · | -63.7% | -40.0% | -35.2% | · | -76.0% | -47.0% | -25.9% | · | -25.6% | |
| Payout Ratio | · | 0.00% | · | · | · | -1.6% | · | · | · | -1.1% | · | · | · | -0.86% | · | · |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| Ricavi | $63M | — | — | $58M | — |
| Margine Operativo % | -111.0% | — | — | -191.4% | — |
| Utile netto | $7M | — | — | $-46M | — |
| EPS Diluito | $-0.07 | — | — | $-2.69 | — |
Stato Patrimoniale
| 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| Rapporto corrente | 2.5 | — | — | 1.3 | — |
| Quick Ratio | 2.2 | — | — | 0.9 | — |
Flusso di cassa
| 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | — | — | — | $-80M | — |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Insider aziendali 1 insider · 1 dirigenti · 0 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| David Jin | Chief Financial Officer | 22 Giugno 2026 A | 1.651.571 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 3 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. ×2 depositi | 03 Gennaio 2025 | 12,40% | Modifica | — | SEC |
| Lindsay A Rosenwald, M.D. | 27 Gennaio 2017 | — | Deposito iniziale | — | SEC |
| Michael S. Weiss | 28 Gennaio 2016 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.